Welcome to the MDI website. Content and updating of information is ongoing on our website, therefore if you cannot find what you are looking for please contact us.
March 3rd, 2021
The Food and Drugs Administration (FDA) in the USA has granted accelerated approval to AMONDYS 45™ (casimersen). AMONDYS 45™ is engineered to treat patients with DMD who have genetic mutations that are suitable for skipping exon 45 of the dystrophin gene. This is the first FDA-approved targeted treatment for patients with this type of mutation and the fifth approval in the Duchenne community. For more details, click on this link https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-amondys-45tm